Last reviewed · How we verify
NCT03504358
A New Prognostic Scoring System for Spontaneous Ruptured Hepatocellular
trial testing Liver resection in Rupture, Spontaneous in 129 participants. Completed in 31 December 2017.
1 May 2015
Quick facts
| Lead sponsor | Huazhong University of Science and Technology |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 129 |
| Start date | 1 January 2005 |
| Primary completion | 1 May 2015 |
| Estimated completion | 31 December 2017 |
Drugs / interventions tested
- Liver resection
Conditions studied
- Rupture, Spontaneous — all drugs for Rupture, Spontaneous →
Sponsor
Huazhong University of Science and Technology
Who can join
Adults 15 to 75, any sex, with Rupture, Spontaneous. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Develop a new scoring system for HCC patients with tumor rupture.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03504358
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Liver resection
Trials testing the same drug.
- NCT06420440 — Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model · Phase 2 · recruiting
- NCT05458115 — Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma · unknown
- NCT05540925 — Vascular Invasion Signatures in cfDNA Support Re-staging of Liver Cancer · completed
- NCT06248528 — Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy. · NA · active not recruiting
- NCT04178759 — Impact of Chemotherapy and Regenerative Markers of Liver Regeneration After Liver Resection for Liver Metastases · NA · unknown
Other Huazhong University of Science and Technology trials
Trials by the same sponsor.
- NCT07502027 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Tr · Phase 4 · not yet recruiting
- NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
- NCT07509866 — Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal · NA · recruiting
- NCT07326943 — Minimum Effective Dose of Ropivacaine for Ultrasound-guided Interscalene Block · NA · recruiting
- NCT07229976 — Clinical Efficacy of Thumbtack Needle for Chronic Insomnia in Perimenopausal and Menopausal Women · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03504358 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huazhong University of Science and Technology
- Last refreshed: 20 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03504358.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing